References
- Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002;61:409–13.
- Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 2007;16:309–17.
- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta- analysis. Arch Intern Med 2005;165:2337–44.
- Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90.
- Racanelli V, Prete M, Minoia C, Favoino E, Perosa E. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008;7:352–8.
- Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 2005;53:781–4.
- Váróczy L, Gergely L, Zeher M, Szegedi G, Illés A. Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study. Rheumatol Int 2002;22:233–7.
- Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010;9:195–9.
- Cheng TM. 2009. Taiwan's national health insurance system: high value for the dollar. In Okma KGH, Crivelli L, editors. Six countries, six reform models: their healthcare reform, experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific. p 171–204.
- Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008;19:887–94.
- Liang JA, Sun LM, Yeh JJ, Lin WY, Chang SN, Sung HC, et al. Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study. Rheumatol Int 2012;32:773–8.
- Chen YJ, Chang YT, Wang CB, Wu CY. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 2010;123:1150.e1–6.
- Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus 2009;18:479–85.
- Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010;9:195–9.
- Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case cohort study. Ann Rheum Dis 2008;67:74–9.
- Lin YS, Lin LC, Huang MH, Huang AJ, Huang YT. Down- regulation of gp130 in nasopharyngeal carcinoma. Am J Rhinol Allergy 2009;23:28–32.
- Allen CT, Judd NP, Bui JD, Uppaluri R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 2012;122:144–57.
- Wanebo HJ, Blackinton D, Kouttab N, Mehta S. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer. Am J Surg 1993;166:389–94.
- Puliaeva I, Puliaev R, Via CS. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun Rev 2009;8:219–23.
- Illes A, Varoczy L, Papp G, Wilson PC, Alex P, Jonsson R, et al. Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy. Scand J Immunol 2009;69:387–400.